SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE RELATED MACULAR DEGENERATION AND DIABETIC RETINOPATHY

摘要

The invention provides a pharmaceutical composition comprising at least one anti-CD25 antibody composition and/or rapamycin or derivatives thereof, in a pharmaceutically and physiologically acceptable carrier, for use in an amount effective for use as a medicament for inhibiting the progression of choroidal neovascularization (CNV) and/or for reducing the amount of anti-VEGF treatments needed by the patient associated with the treatment of age-related macular degeneration (AMD) in a patient undergoing anti-VEGF treatment, and/or as a medicament for use in inhibiting the progression of diabetic retinopathy (DR), and/or for reducing the amount of anti-VEGF treatments needed by the patient associated with the treatment of DR in an amount effective to reduce the amount of anti-VEGF treatments needed by the patient.